BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 17, 2012
 |  BioCentury  |  Strategy

Takeda's Russian push

Takeda builds out Nycomed infrastructure in Russia to launch innovator drugs

Takeda Pharmaceutical Co. Ltd. is building out its Nycomed unit's infrastructure in Russia in preparation for expected changes to Russia's reimbursement system that would transform the country's market from one focused on branded generics to one more able to pay for innovator drugs.

Takeda acquired Nycomed last year for €9.6 billion ($13.6 billion) net of cash and debt (see BioCentury, May 23, 2011).

One of the deal drivers was Takeda's desire to reduce its reliance on North America and Japan, which accounted for 82% of revenues in 2010. The addition of Nycomed took the pharma's revenues from 3% in emerging markets in 2011 to an estimated 13% in 2012.

Russia is the largest emerging market for Takeda, with FY12 revenues forecast at €630 million ($821 million), or 4% of the company's sales.

Jostein Davidsen, head of emerging markets, said the Russian pharmaceuticals market is expected to grow 10% per year over the next five years. Takeda expects to grow faster - at 15% per year - based on Nycomed's history and strong base in that market compared to other players.

Read the full 887 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >